Mon04222019

Robins Global News & Noticias



  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study


SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies.
Cardiovascular diseases1 are the most common cause of death and disability globally and the approximate annual impact in the US includes over:9 million myocardial infarctions8 million people with peripheral artery disease 6 million people diagnosed with Chronic/Congestive Heart Failure (CHF)600,000 people who die of cardiovascular disease each year (1 in every 4 deaths)Pain, diminished quality of life and/or diminished patient life expectancy are associated with advance stages for all of these diseases.RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions. RTX specifically ablates sensory nerves that express the TRPV1 receptor.  These receptors are present in peripheral sensory neurons responsible for the sensation of pain, inflammation, and detection of high heat thresholds. TRPV1 is also found in central sensory ganglia and appear to play a role in integrating inflammatory signals to the brain.  At pharmacological doses of RTX, proprioceptive and motor neurons are not affected. Animal model data generated by academic institutions in the past years support the potential use of RTX in a variety of cardiovascular disorders. Published data key conclusions:Compared to control, RTX administered to the surface of the heart (epicardium) reduced cardiac and renal sympathetic nerve activity in animals who had a myocardial infarction (MI) with resulting chronic heart failure (CHF).  In addition, RTX treatment decreased cardiac fibrosis (remodeling), diastolic dysfunction (Wang et al. Hypertension 2014; Wang et al. J. Physiol 2017) and inflammation.Rats with CHF who have RTX induced ablation of the TRPV1 sensory thoracic and epicardial afferent nerves survived longer than control treated animals.Thoracic epidural RTX administration in spontaneously hypertensive rats reduced blood pressure or prevented the development of ...


Posted: 2019-04-15 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

In-Vitro Diagnostics Market 2023 Growth Insights, Size Expansion, Share Valuation, Industry News Update – Research Report by MRFR

Sun, 07 Apr 2019 20:03:00 GMT

The growth of the Global In-Vitro Diagnostics Market is stemmed from the rise in the prevalence of chronic diseases on a global scale. Diseases such as tuberculosis, diabetes, cancer, and ...

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2019 Results - Earnings Call Transcript

Tue, 12 Feb 2019 11:13:00 GMT

Our PL-5028 is a dual natural peptide A receptor C agonist for use in cardiovascular and fibrotic diseases; including reduction of ... is doing its job and being careful. There is a ...

Daily aspirin does not make for a longer, 'disability-free' life

Wed, 19 Sep 2018 09:02:00 GMT

The final completion date is January 2019. The admission age was 65 and older only for African-American and Hispanic recruits in the U.S. because these groups have a higher risk of developing ...

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2018 Results - Earnings Call Transcript

Tue, 15 May 2018 13:54:00 GMT

Moving on to Palatin's other drug development efforts, we are primarily focused on our Melanocortin Program targeting autoimmune and inflammatory diseases and our naturally peptide program for ...

Moderna Announces Pipeline and Corporate Update

Thu, 14 Sep 2017 04:06:00 GMT

mRNA AZD-8601 is being developed by Moderna’s partner AstraZeneca to express a local and transient surge of vascular endothelial growth factor-A (VEGF-A) as a potential treatment for cardiovascular ...

Related Bing Web Search

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 15 Apr 2019 08:05:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 15 Apr 2019 11:18:00 GMT)

Press Release Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 15 Apr 2019 10:21:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. Apr 15, 2019 at 4:00 AM EDT. ... (RTX) for multiple life-threatening cardiovascular disorders, ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 15 Apr 2019 15:50:00 GMT)

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies.

KAKE.com | Wichita, Kansas News, Weather, Sports ...

(Mon, 15 Apr 2019 10:14:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 15 Apr 2019 09:38:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. ... for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. ... We have just completed a major ...

Sorrento Therapeutics : Expands Resiniferatoxin Clinical ...

(Tue, 16 Apr 2019 15:06:00 GMT)

SAN DIEGO - Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento'), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies.. Cardiovascular diseases1 are the most common cause of death and disability globally and the ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Tue, 16 Apr 2019 05:19:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. Sorrento Therapeutics, Inc. April 15, 2019. SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that its ...

Sorrento Therapeutics Inc. (via Public) / Sorrento ...

(Wed, 17 Apr 2019 00:53:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento'), announced that its Neuro-Therapeutics unit is pursuing clinical ...

SRNE Stock Price Quote & News - Sorrento Therapeutics ...

(Thu, 18 Apr 2019 07:40:00 GMT)

View the real-time SRNE price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Sorrento Therapeutics against related stocks people have also bought like VKTX, NVAX, CPRX, and GERN.

Related News Story Videos From Youtube

Tricuspid Valve Reconstruction for Infective Endocarditis: Operative Highlights


Related Videos On: Tricuspid Valve Reconstruction for Infective Endocarditis: Operative Highlights


Introduction to Atrial Fibrillation by Dr. Kamal Kotak, Sharp HealthCare


Related Videos On: Introduction to Atrial Fibrillation by Dr. Kamal Kotak, Sharp HealthCare


Aortic Aneurysm and Aortic Dissection


Related Videos On: Aortic Aneurysm and Aortic Dissection


Adult Congenital Heart Disease: Bicuspid Aortic Valve


Related Videos On: Adult Congenital Heart Disease: Bicuspid Aortic Valve


Smoking Causes Cancer, Heart Disease, Emphysema


Related Videos On: Smoking Causes Cancer, Heart Disease, Emphysema






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.